Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | ARAF | P10398 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 1.00 |
| ▸ | MYOC | Q99972 | 1/20 | 1.00 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw305074X SCHEMBL29389948 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL149921 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL149922 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL29392050 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL5367163 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL1394784 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL4726411 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL8206335 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL26245253 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL10026597 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258056-A1 | USE OF miR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS | WOODS THOMAS COOPER (US) | 2015-09-17 | — | — | US | claimed |
| WO-2022140246-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2022-06-30 | — | — | WO | disclosed |
| US-9522130-B2 | Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects | WOODS THOMAS COOPER (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150258056-A1 | USE OF miR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS | WOODS THOMAS COOPER (US) | 2015-09-17 | — | — | US | disclosed |
| US-20110243957-A1 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110243957-A1 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010036813-A1 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243957-A1 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION | APP, IAPP, KSR1 | RAF1 10/4885MAP1LC3B 829/4885MAPT 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.